loading page

Sordarin -- the antifungal antibiotic with unique modus operandi
  • +2
  • Yutian Shao,
  • Eliza Molestak,
  • Weike Su,
  • Marek Stankevič,
  • Marek Tchorzewski
Yutian Shao
Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou
Author Profile
Eliza Molestak
Maria Curie-Sklodowska University
Author Profile
Weike Su
Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou
Author Profile
Marek Stankevič
Maria Curie-Sklodowska University
Author Profile
Marek Tchorzewski
Maria Curie-Sklodowska University
Author Profile

Abstract

Fungal infections cause serious problems in many aspects of human life; especially infections by fungal species represent problems in immunocompromised patients. Current antifungal antibiotics target various metabolic pathways, predominantly the cell wall or cellular membrane. However, numerous compounds are available to combat fungal infections, their efficacy is far from being satisfactory and some of them display substantial toxicity. The emerging resistance represents a serious issue as well; thus, there is a considerable need for new anti-fungal compounds with lower toxicity and higher effectiveness. One of the unique antifungal antibiotics is sordarin, the only known compound that acts on the fungal translational machinery per se. It has been shown that sordarin inhibits protein synthesis at the elongation step of the translational cycle, acting on eukaryotic elongation-factor-2. In this review, we are aiming to deliver a robust scientific platform promoting the development of antifungal compounds, especially focusing on molecular action of sordarin.

Peer review status:IN REVISION

17 Jun 2021Submitted to British Journal of Pharmacology
18 Jun 2021Submission Checks Completed
18 Jun 2021Assigned to Editor
02 Jul 2021Reviewer(s) Assigned
10 Aug 2021Review(s) Completed, Editorial Evaluation Pending
11 Aug 2021Editorial Decision: Revise Minor
08 Sep 20211st Revision Received
14 Sep 2021Assigned to Editor
14 Sep 2021Submission Checks Completed